Physitrack: Short-term challenges - Redeye

Redeye provides updated estimates and valuation following Physitrack’s Q2 report. As anticipated, the quarter was softer, reflecting the impact of the strategic shift away from one-time upfront revenue, which dampened growth. Additionally, the cost base remains front-loaded in preparation for Champion Health’s upcoming market expansion. However, the launch is expected to drive growth in the year's second half. Our new fair value range is SEK9-72 (SEK9-75) with a Base case of SEK30 (35).

Länk till analysen i sin helhet: https://www.redeye.se/research/1018242/physitrack-short-term-challenges?utm_source=finwire&utm_medium=RSS